- Home
- LTRN vs ATOS Comparison
LTRN vs ATOS Comparison
Compare LTRN & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LTRN | ATOS |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.6M | 24.4M |
| IPO Year | 2020 | 2010 |
Fundamental Metrics
Financial Performance| Metric | LTRN | ATOS |
|---|---|---|
| Price | $0.67 | $2.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $17.50 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 292.3K | 86.4K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.65 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,758.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.65 | $0.53 |
| 52 Week High | $4.34 | $7.56 |
Technical Indicators
Market Signals| Indicator | LTRN | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 16.54 | 64.66 |
| Support Level | N/A | $2.20 |
| Resistance Level | $1.96 | $2.97 |
| Average True Range (ATR) | 0.10 | 0.27 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 0.97 | 70.94 |
Price Performance
Historical ComparisonAbout LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.